At the end of the treatment, they observed a reduced cardiac ejection fraction and fractional shortening, as well as increased CD4+ and CD8+ T cell infiltration in the myocardium in the anti-PD1 tumor-bearing group. This evidence concerns the gene CD8A and neoplasm.